Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)

Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)

Oncogenic BRAF mutations have been widely described in melanomas and promote tumour progression and chemoresistance. We previously provided evidence that the HDAC inhibitor ITF2357 (Givinostat) targets oncogenic BRAF in SK-MEL-28 and A375 melanoma cells. Here, we show that oncogenic BRAF localises t...

Full description

Bibliographic Details
Main Authors: Adriana Celesia, Marzia Franzò, Diana Di Liberto, Marianna Lauricella, Daniela Carlisi, Antonella D’Anneo, Antonietta Notaro, Mario Allegra, Michela Giuliano, Sonia Emanuele
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:International Journal of Molecular Sciences
Subjects:
HDAC inhibitor
ITF2357
BRAF
melanoma
p53
apoptosis
Online Access:https://www.mdpi.com/1422-0067/24/11/9148

Internet

https://www.mdpi.com/1422-0067/24/11/9148

Similar Items